We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDPH
RNS Number : 1377U
Dechra Pharmaceuticals PLC
20 October 2017
Friday, 20 October 2017
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Pre Annual General Meeting Statement
The Board of Dechra issues the following trading update prior to the Annual General Meeting (AGM) which will take place at 1.00pm today, Friday 20 October 2017, at The Mere Hotel, Chester Road, Knutsford, Cheshire WA16 6LJ.
The Company is pleased to report that performance in the first quarter of our financial year was in line with management expectations, with continued growth across all of its markets.
No other new trading updates are to be made at the AGM today.
Dechra will announce its interim results for the six month period to 31 December 2017 on 26 February 2018.
Hot Features
Premium
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0)
1606 814 730
Richard Cotton, Chief Financial Office: +44 (0)
Officer 1606 814 730
e-mail: corporate.enquiries@dechra.com Office: +44 (0)
1606 814 730
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0)
e-mail: fiona@tooleystreet.com 7785 703 523
Office: +44 (0)
121 309 0099
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.
Market Abuse Regulation (MAR)
The information contained within this announcement may constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMOKCDDFBDDFKD
(END) Dow Jones Newswires
October 20, 2017 02:00 ET (06:00 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
